Antimalarial Drug

Hydroxychloroquine Pill for Multiple Sclerosis

Foothills Medical Centre, Calgary, Canada
Hydroxychloroquine Pill +1 morePhase 2RecruitingResearch Sponsored by University of Calgary

Study Summary

This trial is to test if a combination of two drugs can help reduce disability in people with secondary progressive multiple sclerosis.

Eligible Conditions
  • Secondary Progressive Multiple Sclerosis


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 month follow-up, 6 months follow-up, 12 months follow-up, and 18 months follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 month follow-up, 6 months follow-up, 12 months follow-up, and 18 months follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Timed 25-Foot Walk (T25FW)
Secondary outcome measures
9-Hole Peg Test
Functional Systems and Expanded Disability Status Scale (EDSS)
Modified Fatigue Impact Scale (MFIS)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hydroxychloroquine and IndapamideExperimental Treatment2 Interventions
Oral Hydroxychloroquine, 200mg BID Oral Indapamide, 2.5 mg OD
First Studied
Drug Approval Stage
How many patients have taken this drug
Hydroxychloroquine Pill

Find a site

Who is running the clinical trial?

University of CalgaryLead Sponsor
748 Previous Clinical Trials
583,295 Total Patients Enrolled
7 Trials studying Multiple Sclerosis
306 Patients Enrolled for Multiple Sclerosis

Media Library

Hydroxychloroquine (Antimalarial Drug) Clinical Trial Eligibility Overview. Trial Name: NCT05013463 — Phase 2
Multiple Sclerosis Clinical Trial 2023: Hydroxychloroquine Highlights & Side Effects. Trial Name: NCT05013463 — Phase 2
Multiple Sclerosis Research Study Groups: Hydroxychloroquine and Indapamide
Hydroxychloroquine (Antimalarial Drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05013463 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research include young people in their twenties?

"The minimum age that a patient can be to enroll in this study is 18 and the maximum age is 60."

Answered by AI

Are there any patients who have not yet been enrolled in this research?

"The website provides evidence that this study is still looking for patients to enroll. This research was first posted on October 1st, 2021 and the most recent update was on May 16th, 2022. They are recruiting from just 1 site but need a total of 35 individuals."

Answered by AI

How many individuals are included in this research project?

"That is correct, the trial is still actively recruiting patients. The listing on shows that the study was posted on October 1st 2021 and updated most recently on May 16th 2022. They are hoping to enroll 35 patients from a single site."

Answered by AI

If I meet the requirements, may I join this clinical trial?

"Those suffering from multiple sclerosis and between the ages of 18-60 may be eligible for this trial. So far, 35 patients have been enrolled."

Answered by AI

Has the Hydroxychloroquine Pill undergone FDA approval?

"While Phase 2 trials have not yet provided data to support efficacy, there is enough information indicating Hydroxychloroquine Pill's safety to merit a score of 2."

Answered by AI
~12 spots leftby Sep 2024